Heska Corp (HSKA) was Downgraded by Gabelli & Co to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Gabelli & Co advised their investors in a research report released on Aug 4, 2016.
Many Wall Street Analysts have commented on Heska Corp. Heska Corp was Initiated by Sidoti to “Buy” on Jul 1, 2016.
On the company’s financial health, Heska Corp reported $0.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.18. The company had revenue of $30.00 million for the quarter, compared to analysts expectations of $28.47 million. The company’s revenue was up 25.5% compared to the same quarter last year.
Heska Corp opened for trading at $43.11 and hit $43.845 on the upside on Tusday, eventually ending the session at $43.61, with a gain of 0.46% or 0.2 points. The heightened volatility saw the trading volume jump to 56,407 shares. Company has a market cap of $291 M.
In a different news, on Aug 2, 2016, Kevin S. Wilson (CEO and President) sold 20 shares at $43.95 per share price. According to the SEC, on Jul 11, 2016, Jason A Napolitano (COO, CFO, EVP and Secretary) sold 20,000 shares at $41.00 per share price. On May 10, 2016, Sharon L. Riley (director) sold 5,000 shares at $36.87 per share price, according to the Form-4 filing with the securities and exchange commission.
Heska Corporation develops manufactures markets sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. The Company operates in two segments: Core Companion Animal Health and Other Vaccines Pharmaceuticals and Products. The Core Companion Animal Health segment (CCA) includes primarily for canine and feline use blood testing instruments and supplies digital imaging products software and services and single use products and services such as heartworm diagnostic tests heartworm preventive products allergy immunotherapy products and allergy testing. The Other Vaccines Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production primarily for cattle but also for other animals including small mammals.